XILIO THERAPEUTICS INC
(NASDAQ: XLO)

Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.

1.080

+0.441 (+69.01%)
Range - - -   (-%)
Open 1.920
Previous Close 0.639
Bid Price 3.080
Bid Volume 9
Ask Price 3.170
Ask Volume 10
Volume 34,539,272
Value -
Remark
Delayed prices. Updated at 29 Mar 2024 04:00.
Data powered by
View All Events

Loading Chart...

Please login to view stock data and analysis